Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0Z2JP
|
|||
| Former ID |
DIB011079
|
|||
| Drug Name |
Vi-CRM197
|
|||
| Synonyms |
Bivalent vaccine (Salmonella typhi/Salmonella paratyphi infection/typhoid fever); Broad-range vaccine (Salmonella infections), Novartis Vaccines Institute for Global Health; S tyhphi/CRM-197 conjugate vaccine, Novartis; Bivalent vaccine (Salmonella typhi/Salmonella paratyphi infection/typhoid fever), Novartis Vaccines Institute for Global Health
Click to Show/Hide
|
|||
| Indication | Salmonella infection [ICD-11: 1A09; ICD-10: A02.9] | Phase 2 | [1] | |
| Company |
Novartis Vaccines Institute for Global Health
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT01438996) Extension Study of H01_04TP to Evaluate the Booster Response Induced by Vi-CRM197 in Adults. U.S. National Institutes of Health. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.